Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Objective Experimental studies have reported potential benefit of glucagon-like peptide-1(GLP-1) receptor agonists in preventing diabetic peripheral neuropathy (DPN). We therefore performed a proof-of-concept pilot study to evaluate the effect of exenatide, a GLP-1 agonist, on measures of DPN and cardiovascular autonomic neuropathy (CAN) in patients with type 2 diabetes (T2D). Research Design and Methods Forty-six T2D subjects (age 54±10 years, diabetes duration 8 ± 5 years,HbA1c 8.2 ±1.3%) with mild to moderate DPN at baseline were randomized to receive either twice daily exenatide (n=22) or daily insulin glargine (n= 24). The subjects, with similar HbA1c levels, were followed for 18 months. The primary end point was the prevalence of confirmed clinical neuropathy (CCN). Changes in measures of CAN, other measures of small fiber neuropathy such as intra-epidermal nerve fiber density (IENFD), and quality of life were also analyzed. Results Glucose control was similar in both groups during the study. There were no statistically significant treatment group differences in the prevalence of CCN, IENFD, measures of CAN, nerve conductions studies, or quality of life indices. Conclusions In this pilot study of patients with T2D and mild to moderate DPN, 18 months of exenatide treatment had no significant effect on measures of neuropathy compared with glargine treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1303 · Cited by 2,690 · cited 1×
“Diabetic peripheral neuropathy (DPN) affects nearly two-thirds of patients with diabetes and is a major cause of poor quality of life (1) Despite the proven efficacy of intensive glucose control in delaying or preventing DPN and cardiovascular autonomic neuropathy (CAN) in patients with type 1 diabetes (T1D)(2-4), equ…”
BackgroundSpallone, V., Ziegler, D., Freeman, R., Bernardi, L., Frontoni, S., Pop‐Busui, R., Stevens, M., Kempler, P., Hilsted, J., Tesfaye, S., et al. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1239 · Cited by 957 · cited 1×
“CAN was evaluated at baseline, 12 months, and 18 months with the gold-standard cardiovascular reflex tests (CARTs) (the deep breathing test and the Valsalva maneuver) (19) and measures of HRV obtained during a 5-minute rest and during CARTs using the ANX 3.”
MethodSelf-citationMartin, C. L., Albers, J. W., Pop-Busui, R., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2114 · Cited by 499 · cited 1×
“Intensive glycemic control is essential but insufficient to completely prevent onset or progression of diabetic neuropathy (5,30).”
BackgroundSelf-citationYamamoto, H., Lee, C. E., Marcus, J. N., Williams, T. D., Overton, J. M., Lopez, M. E., Hollenberg, A. N., Baggio, L., Saper, C. B., Drucker, D. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215595 · Cited by 429
Not Available, N. A. (1998) · Diabetologia · doi:10.1007/s001250050924 · Cited by 308
Impaired glucose tolerance and neuropathy
Smith, A. G., & Singleton, J. R. (2008) · The Neurologist · doi:10.1097/nrl.0b013e31815a3956 · Cited by 165
Bharucha, A. E., Charkoudian, N., Andrews, C. N., Camilleri, M., Sletten, D., Zinsmeister, A. R., & Low, P. A. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00153.2008 · Cited by 98 · cited 1×
“The effects on heart rate observed in this study contrast, however, with those observed in the majority of human of trials that evaluated the glucose lowering effects of GLP-1 receptor analogs involving diabetic and/or obese subjects which all reported persistent increase in heart rate, usually associated with signifi…”
ResultGLP‐1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice
Jolivalt, C. G., Fineman, M., Deacon, C. F., Carr, R. D., & Calcutt, N. A. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01431.x · Cited by 87 · cited 1×
“Emerging experimental evidence discussed above and a small human study suggested potential beneficial effect of GLP-1 receptor agonists or dipeptidyl peptidase-4 (DPP-4) inhibitors on measures of DPN via non-glycemic effects (10-14; 21-23).”
Background
Cited by
Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy
Iqbal, Z., Azmi, S., Yadav, R., Ferdousi, M., Kumar, M., Cuthbertson, D. J., Lim, J., Malik, R. A., & Alam, U. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.04.001 · Cited by 487
“However, in a pilot study in patients with type 2 diabetes and mild to moderate DPN, 18 months of treatment with exenatide, compared with glargine, had no effect on neuropathy.(45) In a meta-analysis of data from 10 studies, there was greater remission and lower risks for microvascular and macrovascular disease and mo…”
ResultMolecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets
Dewanjee, S., Das, S., Das, A. K., Bhattacharjee, N., Dihingia, A., Dua, T. K., Kalita, J., & Manna, P. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.06.034 · Cited by 300
12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Callaghan, B. C., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s012 · Cited by 176
Self-citationGoldney, J., Sargeant, J. A., & Davies, M. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05988-3 · Cited by 100
Cao, C., Yang, S., & Zhou, Z. (2019) · Endocrine · doi:10.1007/s12020-019-02055-z · Cited by 99
Metadata
- Authors
- Jaiswal, M., Martin, C. L., Brown, M. B., Callaghan, B., Albers, J. W., Feldman, E. L., & Pop-Busui, R.
- Venue
- Journal of Diabetes and its Complications
- Publisher
- Elsevier BV
- Published
- 2015-11
- Volume
- 29
- Issue
- 8
- Pages
- 1287-1294
- ISSN
- 0891-6632 (ISSN-L)
- 1056-8727
- OpenAlex
- W972810958
- Cited by
- 96
- References
- 8
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study. https://app.cochat.ai/papers/10.1016/j.jdiacomp.2015.07.013
- The paper
- Jaiswal, M., Martin, C. L., Brown, M. B., Callaghan, B., Albers, J. W., Feldman, E. L., & Pop-Busui, R. (2015). Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study. Journal of Diabetes and its Complications. https://doi.org/10.1016/j.jdiacomp.2015.07.013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.